Novobiotic Pharmaceuticals, LLC
Cambridge, MA
- UEI
- GUV4CZLZE5Z2
- CAGE
- 48R19
- Primary NAICS
- 238990 All Other Specialty Trade Contractors
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 767C Concord Ave, Cambridge, MA 02138, USA
- Website
- novobiotic.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Nubad LLC | Greer, SC | 541380 Testing Laboratories and Services |
| Curza Inc. | Salt Lake City, UT | — |
| Arietis Corporation | Boston, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Aimmax Therapeutics Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Debiopharm International SA | Lausanne, VD | — |
About the company
Novobiotic Pharmaceuticals, LLC is a biotechnology company focused on the discovery and development of new antibiotics targeting serious drug resistant infections. They specialize in using their iChip technology to culture previously uncultivated environmental microorganisms and screen them for novel antimicrobial compounds.
Through various prime federal grant awards from the National Institutes of Health and the Defense Health Agency, Novobiotic Pharmaceuticals has conducted research and development related to discovering, testing, and advancing new antibiotic drug candidates such as teixobactin. This includes late stage preclinical development and testing for efficacy against infections like anthrax, tuberculosis, and drug resistant respiratory infections, with the goal of providing new treatment options for dangerous infections that have grown resistant to existing antibiotics. Novobiotic has received over $20 million in federal grant funding to support this research through programs like the Military Medical Research and Development program and grants from the National Institute of Allergy and Infectious Diseases.
Quick answers
Is Novobiotic Pharmaceuticals, LLC registered in SAM.gov?
Yes. Novobiotic Pharmaceuticals, LLC's SAM.gov registration is active through January 2, 2027.
What is Novobiotic Pharmaceuticals, LLC's CAGE code?
Novobiotic Pharmaceuticals, LLC's CAGE code is 48R19, and its Unique Entity ID (UEI) is GUV4CZLZE5Z2.
What is Novobiotic Pharmaceuticals, LLC's most recent federal award?
Novobiotic Pharmaceuticals, LLC's most recent federal grant award is Antifungal discovery from previously uncultivated bacteria (R43AI174320), from National Institute of Allergy and Infectious Diseases (NIH), on May 9, 2023.
On GovTribe
See Novobiotic Pharmaceuticals, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors